Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582490 · ClinicalTrials.gov registry record · Phase 4
Study of EXPAREL in Patients Undergoing Breast Augmentation
A Phase 4 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT01582490 is a Phase 4 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 19 participants.
The verdict
NCT01582490, a Phase 4 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a Phase 4, prospective, open-label, non-randomized, sequential study with two treatment groups differing only in the technique used for EXPAREL administration (instillation or infiltration).
Interventions
- DRUG Instillation - EXPAREL
- DRUG Infiltration - EXPAREL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01582490
The ClinicalTrials.gov registry entry for NCT01582490 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Instillation - EXPAREL is the first listed.
NCT01582490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01582490 about?
NCT01582490 is a clinical study titled "Study of EXPAREL in Patients Undergoing Breast Augmentation". This is a Phase 4, prospective, open-label, non-randomized, sequential study with two treatment groups differing only in the technique used for EXPAREL administration (instillation or infiltration).
What is the current status of trial NCT01582490?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2012-04. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01582490?
The interventions under investigation include: Instillation - EXPAREL (DRUG), Infiltration - EXPAREL (DRUG).
Who is sponsoring clinical trial NCT01582490?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.